Cardiology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

New oral anticoagulants: Apixaban is not associated with an increase in myocardial infarction

The coagulation system contributes greatly to the evolution of myocardial infarction ( MI ). Anticoagulation may reduce the occurrence of myocardial infarction as monotherapy or with concomitant use of Acetylsalicylic acid ( Aspirin ).

Activated factor X antagonists ( anti-Xa ) and direct thrombin inhibitors have promising results in various indications in non-inferiority trials. However, results regarding their cardiovascular safety are heterogeneous.

Researchers have systematically evaluated the risk of myocardial infarction and mortality in patients receiving the new-generation oral anti-Xa agent Apixaban ( Eliquis ).

Efficacy measures included frequency of myocardial infarction, cardiovascular and overall mortality.

Outcome parameters of randomized, controlled clinical trials ( RCTs ) were pooled with a random-effects model. Between January 2000 and December 2013, 12 RCTs comprising 54,054 patients were identified.

Based on the pooled results, there was no increase in the risk of myocardial infarction in patients treated with Apixaban [ odds ratio ( OR ) 0.90; 95 % confidence interval ( CI ) 0.77-1.05; p = 0.17 ] compared to different controls.

Cardiovascular and overall mortality with Apixaban was comparable to the control groups ( OR=0.88; 95 % CI 0.72-1.06; p = 0.18, OR=0.89; 95 % CI 0.77-1.03; p = 0.11, respectively ).

The pooled risk of major bleeding was lower in the Apixaban treated groups ( OR=0.84; 95 % CI 0.62-1.12; p = 0.23 ) however this reached significant level only in subgroup analysis of trials with anticoagulant regimes in the control ( OR=0.66; 95 % CI 0.51-0.87; p = 0.003 ).

In conclusion, in a broad spectrum of patients and compared to different controls Apixaban treatment was not associated with an increase in myocardial infarction or mortality. ( Xagena )

Tornyos A et al, J Thromb Thrombolysis 2014; Epub ahead of print